Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atai Beckley N.V (ATAI : NSDQ)

• Company Description    AtaiBeckley N.V. is a clinical-stage biopharmaceutical company which focused on mental health treatments. AtaiBeckley N.V., formerly known as atai Life Sciences, is based in NEW YORK. Number of Employees: 54

• Price / Volume Information    Yesterday's Closing Price: $4.09 Daily Weekly Monthly 20 Day Moving Average: 2,902,688 shares Shares Outstanding: 363.19 (millions) Market Capitalization: $1,485.45 (millions) Beta: 1.61 52 Week High: $6.75 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.05% -6.89% 12 Week -24.95% -26.16% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL PROF. J.H. BAVINCKLAAN 7 - AMSTELVEEN, P 1183 NLD ph: 49-89-2153-9035 fax: - ir@ataibeckley.com http://www.ataibeckley.com

• General Corporate Information    Officers Srinivas Rao - Chief Executive Officer Christian Angermayer - Chairman Anne Johnson - Chief Financial Officer Sabrina Martucci Johnson - Director Amir Kalali - Director Peer Information Atai Beckley N.V (CORR.) Atai Beckley N.V (RSPI) Atai Beckley N.V (CGXP) Atai Beckley N.V (BGEN) Atai Beckley N.V (GTBP) Atai Beckley N.V (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N0731H103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/16/26 Share - Related Items Shares Outstanding: 363.19 Most Recent Split Date: (:1) Beta: 1.61 Market Capitalization: $1,485.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.15 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -75.00% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: 1,772.50% vs. Previous Quarter: 4.17% ROE 12/31/25 - - 09/30/25 - -107.70 06/30/25 - -85.43 ROA 12/31/25 - - 09/30/25 - -78.65 06/30/25 - -64.38 Current Ratio 12/31/25 - - 09/30/25 - 7.90 06/30/25 - 4.02 Quick Ratio 12/31/25 - - 09/30/25 - 7.90 06/30/25 - 4.02 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -5,106.46 06/30/25 - -5,180.12 Book Value 12/31/25 - - 09/30/25 - 0.67 06/30/25 - 0.72 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.02 06/30/25 - 0.02 Debt-to-Capital 12/31/25 - - 09/30/25 - 1.49 06/30/25 - 1.79

Powered by Zacks Investment Research ©